DUBLIN–(BUSINESS WIRE)–The “Cell Therapy Media Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Type of Product, Type of Cell Therapy, DUBLIN–(BUSINESS WIRE)–The “Cell Therapy Media Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Type of Product, Type of Cell Therapy,

Cell Therapy Media Market Trends and Global Forecasts to 2035: Commercial Scale to Drive Market Growth, Accounting for 75% of Total Demand by 2035 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Cell Therapy Media Market: Industry Trends and Global Forecasts, Till 2035 – Distribution by Type of Product, Type of Cell Therapy, Scale of Operation, Type of End User and Key Geographical Regions” has been added to ResearchAndMarkets.com’s offering.

The global cell therapy media market is projected to grow from USD 1.6 billion in the current year to USD 4.5 billion by 2035, with a CAGR of 11.1%. This growth is primarily driven by advancements and the confirmed efficacy of FDA-approved cell therapies for cancer, rare diseases, and chronic conditions. Over 1,000 clinical trials centered on cell therapies have been registered since 2019, with more than 35 therapies reaching the market. Recent approvals include Breyanzi, CarvyktiT, and Abecma.

Due to stringent regulations in producing cell therapy consumables, over 90% of developers outsource products like culture media and extracellular matrices to expert suppliers, with more than 80 companies offering over 450 types of raw materials. Many suppliers boast GMP-certified facilities catering to diverse cells, including T-cells and stem cells.

Innovation and partnerships in this realm are anticipated to rise, potentially transforming patient care and expanding regenerative medicine.

The report highlights several key industry insights:

  • With over 450 kits, media, and reagents, providers cater to both research and therapeutic needs.
  • Over 80 companies operate globally, predominantly emerging players from North America.
  • The majority of available kits focus on reagents for stem cell therapies, with most stored refrigerated.
  • Media is offered mainly in 100 to 500 ml volumes by nearly 90% of developers.
  • Reagents serve a variety of discovery-scale functions, such as cell expansion.
  • Matrices are well-distributed by ECM coating type and formulation, typically with 1 to 1.5 years of shelf life.
  • Providers enhance technologies and expand portfolios to remain competitive.
  • Strategic initiatives, including partnerships and expansions, bolster company capabilities.
  • Cost considerations significantly influence consumable adoption in manufacturing processes.

The commercial scale of operation is expected to account for 75% of total demand by 2035, propelled by anticipated multiple therapy approvals. A transition from animal-based to animal component-free formulations and strict regulatory guidelines are likely to fuel the market, maintaining an annual growth rate of 11.1%.

By segmentation, extracellular matrices represent the fastest-growing product segment. T-cell therapy is anticipated to dominate the market, driven by the ongoing evaluation of NK cell therapies across numerous clinical studies. The commercial scale is predicted to drive market expansion, with industry players contributing significantly. North America holds the largest market share, though Latin America’s market is expected to grow rapidly.

Noteworthy players include BD Biosciences, Bio-Techne, CellGenix, Corning, and others. A report built on discussions with industry stakeholders offers extensive coverage on market segments, offering insights into market forecast, landscape, competitiveness, brand positioning, and partner collaborations.

Reasons to Buy the Report:

  • Comprehensive market analysis with detailed revenue projections aids strategic decisions for established leaders and newcomers.
  • Competitive landscape insights enable businesses to optimize positioning and strategy development.
  • Provides understanding of market dynamics, vital for capitalizing on growth opportunities.

Additional Benefits:

  • Complimentary PPT Insights and Excel Data Packs
  • 15% Free Content Customization
  • Report Walkthrough with the Research Team

Key Attributes

Report AttributeDetails
No. of Pages250
Forecast Period2025-2035
Estimated Market Value (USD) in 2025$1.6 Billion
Forecasted Market Value (USD) by 2035$4.5 Billion
Compound Annual Growth Rate11.1%
Regions CoveredGlobal

Key Topics Covered

1. PREFACE

  • 1.1. Introduction
  • 1.2. Key Market Insights
  • 1.3. Scope of the Report
  • 1.4. Research Methodology
  • 1.5. Frequently Asked Questions
  • 1.6. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Context and Background
  • 3.2. Introduction to Cell Therapies
  • 3.3. Comparison of Cell Therapies with Other Biopharmaceuticals
  • 3.4. Classification of Cell Therapy Products
  • 3.5. Overview of Cell Therapy Development and Manufacturing
  • 3.6. Role of Raw Materials in Cell Therapy Development and Manufacturing
  • 3.7. Types of Cell Therapy Consumables
  • 3.8. Key Challenges Associated with Manufacturing of Cell Therapy Consumables
  • 3.9. Future Perspectives

4. MARKET OVERVIEW

  • 4.1. Chapter Overview
  • 4.2. List of Cell Therapy Kit Providers
  • 4.3. List of Cell Therapy Media Providers
  • 4.4. List of Cell Therapy Reagent Providers
  • 4.5. List of Cell Therapy Extracellular Matrix Providers

5. COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Key Assumptions and Parameters
  • 5.3. Methodology
  • 5.4. Cell Therapy Consumables Providers: Company Competitiveness Analysis
  • 5.5. Cell Therapy Kit Providers
  • 5.6. Cell Therapy Media Providers
  • 5.7. Cell Therapy Reagent Providers
  • 5.8. Cell Therapy Extracellular Matrix Providers

6. BRAND POSITIONING OF KEY INDUSTRY PLAYERS

  • 6.1. Chapter Overview
  • 6.2. Scope and Methodology
  • 6.3. Brand Positioning: STEMCELL Technologies
  • 6.4. Brand Positioning: Miltenyi Biotec
  • 6.5. Brand Positioning: Thermo Fisher Scientific
  • 6.6. Brand Positioning: Takara Bio
  • 6.7. Brand Positioning: GeminiBio

7. COMPANY PROFILES

  • 7.1. Chapter Overview
  • 7.2. STEMCELL Technologies
  • 7.3. Miltenyi Biotec
  • 7.4. Thermo Fisher Scientific
  • 7.5. Bio-Techne
  • 7.6. Irvine Scientific
  • 7.7. Lonza
  • 7.8. Sartorius
  • 7.9. BD Biosciences
  • 7.10. Corning
  • 7.11. CellGenix

8. RECENT DEVELOPMENTS AND INITIATIVES

  • 8.1. Chapter Overview
  • 8.2. Partnership Models
  • 8.3. Cell Therapy Consumables: Partnerships and Collaborations
  • 8.4. Cell Therapy Consumables: Mergers and Acquisitions
  • 8.5. Cell Therapy Consumables: Recent Expansions

9. LIKELY PARTNER ANALYSIS FOR CELL THERAPY CONSUMABLE PROVIDERS

  • 9.1. Chapter Overview
  • 9.2. Scoring Criteria and Key Assumptions
  • 9.3. Scope and Methodology
  • 9.4. Key Potential Strategic Partners for Cell Therapy Consumable Providers

10. ROOTS ANALYSIS PRICING STRATEGY

  • 10.1. Chapter Overview
  • 10.2. Roots Analysis Pricing Strategy Framework

11. DEMAND ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Scope and Methodology
  • 11.3. Global Demand for Cell Therapy Consumables
  • 11.4. Analysis by Scale of Operation
  • 11.5. Analysis by Geography

12. MARKET FORECAST AND OPPORTUNITY ANALYSIS

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions and Methodology
  • 12.3. Global Cell Therapy Consumables Market, Till 2035
  • 12.4. Cell Therapy Consumables Market: Analysis by Type of Product
  • 12.5. Cell Therapy Consumables Market: Analysis by Type of Cell Therapy
  • 12.6. Cell Therapy Consumables Market: Analysis by Scale of Operation
  • 12.7. Cell Therapy Consumables Market: Analysis by Type of End-User
  • 12.8. Cell Therapy Consumables Market: Analysis by Geography

13. UPCOMING TRENDS AND FUTURE GROWTH OPPORTUNITIES

  • 13.1. Chapter Overview
  • 13.2. Emerging Trends Related to Cell Culture Media
  • 13.3. Automation of Cell Therapy Manufacturing Processes
  • 13.4. Single Use Systems and Technologies in Cell Therapy Manufacturing

14. CONCLUDING REMARKS

15. INTERVIEW TRANSCRIPTS

  • 15.1. Chapter Overview
  • 15.2. Company A
  • 15.3. Company B
  • 15.4. Company C

A selection of companies mentioned in this report includes, but is not limited to:

  • Accellta
  • Acer Therapeutics
  • ACROBiosystems
  • Activartis Biotech
  • AddLife
  • Adicet Bio
  • Aduro Biotech
  • Advanced BioMatrix (Acquired by BICO)
  • Advent Bioservices
  • AGC Biologics
  • AgenTus Therapeutics
  • Agilent Technologies
  • Ajinomoto
  • Akadeum Life Sciences
  • Akron Biotech
  • Allele Biotechnology and Pharmaceuticals
  • Allife Medical Science and Technology
  • Allogene Therapeutics
  • Altor BioScience
  • American CryoStem
  • Amphera
  • AMSBIO
  • ANI Pharmaceuticals
  • apceth Biopharma
  • Applied Biological Materials
  • Applied Cells
  • Arbele
  • Arcline Investment Management
  • Argos Therapeutics
  • Aspire Health Science
  • Asterias Biotherapeutics
  • ATCC
  • Athersys
  • Atlantis Bioscience
  • Atreca
  • Aurora Biopharma
  • Austrianova
  • Autolus
  • Avantor
  • AVAX Technologies
  • Axion BioSystems
  • Axol Bioscience
  • and many more!

For more information about this report visit https://www.researchandmarkets.com/r/gsb1g0

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./ CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Market Opportunity
Cellframe Logo
Cellframe Price(CELL)
$0.103
$0.103$0.103
-1.24%
USD
Cellframe (CELL) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact service@support.mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

The Contrarian Truth: Why Bitcoin and Ethereum Prices Defy Social Media Sentiment

The Contrarian Truth: Why Bitcoin and Ethereum Prices Defy Social Media Sentiment

BitcoinWorld The Contrarian Truth: Why Bitcoin and Ethereum Prices Defy Social Media Sentiment Have you ever noticed that when everyone on social media is screaming
Share
bitcoinworld2025/12/20 07:45
Record instroom Bitcoin-ETF’s – richting $120.000?

Record instroom Bitcoin-ETF’s – richting $120.000?

Connect met Like-minded Crypto Enthusiasts! Connect op Discord! Check onze Discord   De markt voor Bitcoin ETF’s laat wederom een opvallende trend zien. De afgelopen week werd de grootste instroom sinds juli geregistreerd, een ontwikkeling die de aandacht van zowel institutionele als particuliere beleggers trekt. Deze instroom zorgt voor nieuwe speculatie over de vraag of Bitcoin binnenkort de grens van 120.000 dollar kan doorbreken. Laten we dit hieronder nader bekijken. Grootste instroom sinds juli Volgens recente marktgegevens wist de Amerikaanse spot Bitcoin ETF’s een instroom te krijgen ver boven de gemiddelde niveaus van de afgelopen weken. Alleen al op 16 september werd meer dan 290 miljoen dollar netto in deze fondsen gestort. Daarmee markeert dit de zevende opeenvolgende dag met positieve instroom, een duidelijk teken dat institutionele belangstelling opnieuw toeneemt. De grootste bijdrage kwam van BlackRock’s iShares Bitcoin Trust, dat meer dan 200 miljoen dollar stortte. Ook de ETF’s van Fidelity en Ark lieten grote instroom zien. Kortom, de instroom blijft positief. U.S. spot Bitcoin ETFs Ignite with a $553M daily inflow, pushing a four-day streak to $1.7B. Ether ETFs also saw a resurgence with $113M in new funds. #Bitcoin #ETF #ETHhttps://t.co/zZiNqtKSEm — Cryptonews.com (@cryptonews) September 12, 2025 Hoe instroom prijsondersteuning biedt De sterke instroom in Bitcoin ETF’s is meer dan een mijlpaal. Het laat zien hoe de vraag naar Bitcoin groeit vanuit institutionele hoek en dat deze vraag niet voor een keer is, maar structureel is. Omdat de instroom de hoeveelheid nieuw geminde Bitcoin overtreft, ontstaat er een overschot qua vraag dat de prijs positief kan beïnvloeden. Dit verschil tussen aanbod en vraag zorgt ervoor dat het dalende risico wordt beperkt. Wanneer institutionele beleggers via ETF’s posities opbouwen, gebeurt dit bovendien vaak met een langere beleggingshorizon. Dat geeft de markt extra stabiliteit, zeker in een periode waarin onzekerheden rondom rente en macro-economie nog altijd spelen. Signaalfunctie voor beleggers Voor beleggers in de crypto markt hebben deze cijfers een signaalfunctie. Het vertrouwen dat grote institutionele spelers door miljarden te alloceren in gereguleerde beleggingsproducten bevestigt dat Bitcoin steeds meer gekocht wordt in de traditionele financiële wereld. Dit momentum werkt vaak door naar de bredere markt, omdat particuliere beleggers dit zien als bevestiging dat de trend omhoog sterker wordt. Ook technische analyse wijst op een belangrijke fase. De koers van Bitcoin beweegt rond de 118.000 dollar, een weerstandsniveau dat al meerdere keren is getest. Het momentum dat voortkomt uit de ETF instroom kan de kracht geven om dit niveau te doorbreken en een nieuwe fase van prijsstijging richting 120.000 dollar in te luiden. Op korte termijn richting de $120.000? Hoewel niemand met zekerheid kan voorspellen of Bitcoin dit niveau direct zal bereiken, biedt de huidige context sterke aanwijzingen dat de kans aanwezig is. De combinatie van record instroom, institutioneel vertrouwen en een gunstig technisch analyse vormt een krachtige mix. Beleggers doen er goed aan om rekening te houden met de invloed van externe factoren zoals beleidsbesluiten van de Federal Reserve. Best wallet - betrouwbare en anonieme wallet Best wallet - betrouwbare en anonieme wallet Meer dan 60 chains beschikbaar voor alle crypto Vroege toegang tot nieuwe projecten Hoge staking belongingen Lage transactiekosten Best wallet review Koop nu via Best Wallet Let op: cryptocurrency is een zeer volatiele en ongereguleerde investering. Doe je eigen onderzoek.   Het bericht Record instroom Bitcoin-ETF’s – richting $120.000? is geschreven door Timo Bruinsel en verscheen als eerst op Bitcoinmagazine.nl.
Share
Coinstats2025/09/18 01:31
Q2 Market Insights: Bitcoin regains dominance in risk-averse environment, ETFs remain critical to market structure

Q2 Market Insights: Bitcoin regains dominance in risk-averse environment, ETFs remain critical to market structure

The market will show a downward trend in the short term, and then rebound and set new highs in the second half of the year.
Share
PANews2025/04/28 19:40